G

Company · Healthtech & Bio

Gate2Brain

gate2brain.com ↗ ·Barcelona

Gate2Brain is a Barcelona-based biotech spun out of IRB Barcelona that develops peptide-based "shuttle" technology to carry drugs across biological barriers such as the blood-brain barrier. Its lead candidate, G2B-002, targets rare pediatric brain cancers (e.g. DIPG) and holds Orphan Drug Designation from both the EMA and FDA; the company also licenses its shuttle-peptide platform to pharma partners. Funded largely through EU/EIC grants, corporate venture programs, business angels, and a recent €7M strategic investment from Shilpa Biocare (June 2026).

Founded

2020

Founders

3

News

0

Rounds

3

Investors

5

SectorsBiotech, Drug Delivery, Peptide Therapeutics, Oncology, Pharma Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 4 Aug 2026

Founders

E

Esther Riambau

Business Development Advisor (Co-founder)

G

Gloria Sanclimens

COO (Co-founder)

M

Meritxell Teixidó

CEO & CSO (Co-founder)

Global models

No comparables on record yet.

Investors 5

B

Banco Sabadell (BStartup)

www.bstartup.com ↗

Investor Spain

bstartup.bancsabadell.com/en

European Innovation Council (EIC)

eic.ec.europa.eu

Investor Luxembourg

F

Fundación Botín

www.fundacionbotin.org ↗

Investor Spain

S

Shilpa Biocare

Investor India

Funding rounds 3

Other · €7M

Blood-brain-barrier drug-delivery biotech (UB/IRB spin-off) secured €7M from strategic partner Shilpa Biocare (30.4% stake) — its largest ra…

2026-06-16

Other · €2.5M

Gate2Brain is a spin-off of IRB Barcelona, the University of Barcelona and Sant Joan de Déu. Its peptide technology carries drugs across the…

2022-12-21

Seed · €100K

Gate2Brain, a spin-off of IRB Barcelona, the University of Barcelona and Sant Joan de Déu that uses shuttle peptides to carry drugs across t…

2020-12-29

News & media

No coverage on record yet.